Sonelokimab is under clinical development by MoonLake Immunotherapeutics and currently in Phase II for Psoriatic Arthritis. According to GlobalData, Phase II drugs for Psoriatic Arthritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sonelokimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sonelokimab (M-1095) is under development for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis(r-axSpA) and hidradenitis suppurativa. The drug candidate is administered subcutaneously. M1095 is a trivalent bi-specific nanobody that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F. The drug candidate is developed on basis of nanobody technology. It was also under development for rheumatoid arthritis.
MoonLake Immunotherapeutics overview
MoonLake Immunotherapeutics (MoonLake), formerly Helix Acquisition, is a biopharmaceutical company that develops and markets medicines for immunologic diseases for the treatment of inflammatory skin and joint diseases. The company is headquartered in Zug, Switzerland.
For a complete picture of Sonelokimab’s drug-specific PTSR and LoA scores, buy the report here.